Product Description
Aztreonam injection is used to treat certain infections that are caused by bacteria, including respiratory tract (including pneumonia and bronchitis), urinary tract, blood, skin, gynecological, and abdominal (stomach area) infections, that are caused by bacteria. Aztreonam is in a class of medications called monobactam antibiotics. (Sourced from: https://medlineplus.gov/druginfo/meds/a687010.html)
Mechanisms of Action: PBP Antagonist,Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Cystic Fibrosis
Known Adverse Events: Abdominal Pain | Chest Pain | Pain Unspecified | Cystic Fibrosis
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Bulgaria, China, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Romania, Russia, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Communicable Diseases|Intraabdominal Infections|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Pyelonephritis|Urinary Tract Infections
Phase 2: Bronchiectasis|Gram-Negative Bacterial Infections|Sepsis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| C3601008 | P2 |
Recruiting |
Communicable Diseases|Gram-Negative Bacterial Infections |
2026-08-17 |
|
| C3601008 | P2 |
Unknown Status |
Sepsis|Gram-Negative Bacterial Infections|Urinary Tract Infections|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated |
2025-12-24 |
|
| VitalBE | P2 |
Recruiting |
Bronchiectasis |
2025-09-30 |
|
| 2021-001396-16 | P3 |
Active, not recruiting |
Urinary Tract Infections|Pyelonephritis|Pneumonia, Ventilator-Associated|Pneumonia, Bacterial |
2025-04-21 |